RxDoctor Payments Data

Hima Illindala, MD

Internal Medicine · Las Vegas, NVNPI 1083604102

Payments from drug & device makers

$2,447in general payments, 2019–2025

Across 134 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$456
  • Novo Nordisk$304
  • Lilly USA, LLC$298
  • Johnson & Johnson$293
  • Pfizer$269
  • Amgen$212
  • plus $615 from 7 others

What the payments were for

  • Food & beverage$2,447100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,447 in reported general payments places this provider in the 80th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$31,461
Medicare patients
106
Services billed
355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$60,699
OzempicSemaglutide27$53,000
XareltoRivaroxaban26$45,024
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$30,804
ProliaDenosumab14$24,343
JardianceEmpagliflozin15$24,263
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$22,755
MounjaroTirzepatide12$17,013
LinzessLinaclotide22$16,666
Spiriva RespimatTiotropium Bromide12$10,269
FarxigaDapagliflozin Propanediol11$8,759
SymbicortBudesonide/Formoterol Fumarate16$5,595
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen195$5,266
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$4,637
Levothyroxine Sodium474$4,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$269$60,69944 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$185$57,28744 claims
Novo NordiskOzempic$304$53,00027 claims
Johnson & JohnsonXarelto$293$45,02426 claims
GSKTrelegy Ellipta$456$30,80426 claims
AmgenProlia$212$24,34314 claims
Lilly USA, LLCMounjaro$298$17,01312 claims
AstraZenecaFarxiga, Symbicort$99$14,35427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →